Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction
| Autor: | Mingsong Li, Le Liu, Hongwei Zhou, Ye Chen, Gary D. Wu, Yunsheng Yang, Yuqiang Nie, Anupriya Tripathi, Qian-Yun Lin, Amnon Amir, Minhu Chen, Zhenjiang Zech Xu, Side Liu, Youlian Zhou, Yan He, Rob Knight, Antonio Gonzalez, Fachao Zhi |
|---|---|
| Přispěvatelé: | Ercolini, Danilo |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Physiology lcsh:QR1-502 Crohn's Disease Disease Gut flora Autoimmune Disease Biochemistry Gastroenterology Inflammatory bowel disease digestive system Microbiology Oral and gastrointestinal lcsh:Microbiology Host-Microbe Biology 03 medical and health sciences fluids and secretions 0302 clinical medicine inflammatory bowel disease Internal medicine Genetics medicine Molecular Biology Ecology Evolution Behavior and Systematics biology gut microbiota Clostridiales biology.organism_classification medicine.disease Ulcerative colitis Infliximab digestive system diseases QR1-502 Computer Science Applications infliximab treatment 030104 developmental biology Modeling and Simulation 030211 gastroenterology & hepatology Calprotectin Digestive Diseases Dysbiosis disease activity Research Article medicine.drug |
| Zdroj: | mSystems, Vol 3, Iss 1 (2018) mSystems, vol 3, iss 1 Zhou, Y; Xu, ZZ; He, Y; Yang, Y; Liu, L; Lin, Q; et al.(2018). Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems, 3(1). doi: 10.1128/mSystems.00188-17. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/0ht2v5sc mSystems, Vol 3, Iss 1, p e00188-17 (2018) mSystems |
| ISSN: | 2379-5077 |
| DOI: | 10.1128/mSystems.00188-17 |
| Popis: | In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes. Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn’s disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of Actinobacteria and Proteobacteria (Enterobacteriaceae) and a relative decrease in the levels of Firmicutes (Clostridiales) were strongly correlated with IBD severity (P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales, predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn’s disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD. IMPORTANCE In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|